APA (7th ed.) Citation

Suh, K., Carlson, J., & Garrison, L. (2016). PND23 - Projecting the Potential Cost Effectiveness of Ocrelizumab Versus Standard Care in Primary Progressive Multiple Sclerosis Patients Under Alternative Pricing Scenarios. Value in Health, 19(3), A62. https://doi.org/10.1016/j.jval.2016.03.200

Chicago Style (17th ed.) Citation

Suh, K., JJ Carlson, and LP Garrison. "PND23 - Projecting the Potential Cost Effectiveness of Ocrelizumab Versus Standard Care in Primary Progressive Multiple Sclerosis Patients Under Alternative Pricing Scenarios." Value in Health 19, no. 3 (2016): A62. https://doi.org/10.1016/j.jval.2016.03.200.

MLA (9th ed.) Citation

Suh, K., et al. "PND23 - Projecting the Potential Cost Effectiveness of Ocrelizumab Versus Standard Care in Primary Progressive Multiple Sclerosis Patients Under Alternative Pricing Scenarios." Value in Health, vol. 19, no. 3, 2016, p. A62, https://doi.org/10.1016/j.jval.2016.03.200.